All News
2022 Rheumatology Year in Review
2022 was a year of recovery, discovery, and some losses. While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.
Read Article
Lubricin as a Treatment Target in Gout?
d
EurekAlert!
Many Americans think of gout as a disease from a bygone era, akin to rickets or scurvy. The condition commonly afflicted the rich and royal, including American historical figures such as Benjamin Franklin and Thomas Jefferson.
Read Article
Drug Price Increases Continue in 2023
Reuters reports that in 2023, drug makers intend to increase the price of over 350 drugs.
Read Article
2022 Match - Strong Appeal of Adult Rheumatology, Less So in Pediatric Rheumatology
The ACR is pleased to announce another successful recruitment season and welcomes this impressive pool of applicants to the field of rheumatology.
https://t.co/XEQCq5Pnnt https://t.co/quvxT9njI4
Links:
Dr. John Cush RheumNow ( View Tweet)
Extreme Global Costs of Physical Inactivity
A global, population-based study shows that physical inactivity is not only an important modifiable risk factor for NCDs and mental health conditions, it also imparts a considerable health and economic burden.
https… https://t.co/eZEW6LGpiL
Dr. John Cush RheumNow ( View Tweet)
Should Kids w/ MIS-C get the COVID vaccine? Yes - study of 385 pt > 5 yrs w/ Hx of multisystem inflammatory syndrome showed no serious adverse events after COVID-19 vaccination. The safety profile of COVID-19 vax is same as gen population https://t.co/dr2QBQsMhE? https://t.co/WbsUuYEsez
Links:
Dr. John Cush RheumNow ( View Tweet)
The Dartmouth Hitchcock Medical Center (DHMC) is searching for a new Chief of the Section of Rheumatology - one who is dynamic, experienced, future-oriented academic Rheumatologist https://t.co/TD6gjWAzZu https://t.co/p4NSe6VtKD
Links:
Dr. John Cush RheumNow ( View Tweet)
The Daily Mail in the UK features a long review of Hx of #Gout (Disease of Kings) & being on the rise in the UK - features a video interview with Professor Philip Conahan (one of our speakers at RheumNow Live 2023!) https://t.co/dNC71DwXTf https://t.co/ZtmQgx5aHc https://t.co/2D3HE0GFO5
Dr. John Cush RheumNow ( View Tweet)
Weekly (Ozempic) semaglutide SC was given for obesity, 3-6 mos to 408 pts with BMI> 27. Wt loss was 5.9% (6.7 kg) @3 mos & 10.9% (12.3 kg) @6 mos. 55%) had >10% & 8% had > 20% wt loss. NIDDM pts had less wt loss vs non-DM pts. https://t.co/05O6hlNm2G https://t.co/ppxjLOE03B
Links:
Dr. John Cush RheumNow ( View Tweet)
520 RA pts were screened with FibroScan (liver fibrosis)- F3 or F4 liver fibrosis seen 13.3% of controls vs 12.7% arthritis pts. MTX was not significantly correlated w/ higher FS scores. Liver stiffness was correlated w/ BMI, waist, male , age. https://t.co/NzXfbYsXUu
Links:
Dr. John Cush RheumNow ( View Tweet)
RWCS 2023, Ask the Consultant: Join speakers Anna Postolova, MD & Uma Mahadevan, MD (.@UmaMahadevanIBD) as they cover crucial topics from their personal perspectives, supplemented by literature review, followed by audience Q&A, & discussion. Register here: https… https://t.co/CLqysAAfpA
RWCS RWCSmtg ( View Tweet)
Dr. Kristi Kuhn & Univ of Colorado researchers have linked RA risk with the gut bacterium Subdoligranulum didolesgii. This could be pathogenically important and supports their "Mucosal origins hypothesis" to RA risk https://t.co/xDyejVR8MW https://t.co/M663ziXOcT https://t.co/y7zpukZah5
Dr. John Cush RheumNow ( View Tweet)
Differential Dx of hyperferritinemia (≥500 μg/) in critically ill ICU pts includes: sepsis, liver disease/failure, hematological malignancy, HLH. Single center study of 2583 patients https://t.co/yuqJcyLIP5 https://t.co/vHLqJGP4mv
Links:
Dr. John Cush RheumNow ( View Tweet)
40 yoF with Chronic cough and dyspnea - Lung Fibrosis in Systemic Sclerosis https://t.co/4NYa0l9Dci https://t.co/XTDLKPtrkH
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheums manage #RA. But patients have to manage RA and their lives - I wish we could provide better guidance to our patients about Life with RA. Heres one patient from Wash, DC who accomplished SO MUCH in 2022 and she has RA! @hirokonishimura https://t.co/QStFGZLsTR https://t.co/Q7GoYQYvwx
Links:
Dr. John Cush RheumNow ( View Tweet)
Gilead Sciences and EVOQ Therapeutics have a new 2023 partnership to develop immunotherapies for RA & SLE - using NanoDisc technology with lymph-targeted delivery of disease-specific-antigens. Gilead has IRAK4 inhibitor, GS-5718in Phase I https://t.co/kanUXUhMSm https://t.co/ZaDH1ueWrl
Links:
Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine significantly lowers Alzheimer’s and dementia risk. Study of g 109,124 #RA pts starting HCQ or MTX. showed an 8-16% lower risk. https://t.co/q516bZPOq5 https://t.co/2xdOa8pVAv
Dr. John Cush RheumNow ( View Tweet)
Humira biosimilars became available in EU 10/18; and will soon be available in the USA w/ Amjevita (Amgen) available Jan 2023 & 6 others (Pfizer, BI, Samsung, Coherus, Sandoz, Biocon) after July 2023. https://t.co/m8cdJgM7UC
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective Claims analysis 1663 #SLE pts shows pts w/ lupus nephritis (LN, 2916) had higher Charlson Comorbidity scores ≥4 (72 vs 14%) & inpatient (41 vs 17%). LUPUS FLARES were more (61 vs 54%), more severe (11 vs 5%) & twice the cost https://t.co/tXI7SSalaV https://t.co/z0SorOQilb
Links:
Dr. John Cush RheumNow ( View Tweet)
Medical (AKA surgical) masks are not inferior to N95 fitted masks. A study of 1009 medical workers in 4 countries caring for COVID+ infected patients shows equal rate of PCR+ COVID tests (10.5% vs 9.3% +) (HR 1.14 [95% CI, 0.77 to 1.69]) https://t.co/wTuLHcOxlO https://t.co/gjqfLOU7JW
Links:
Dr. John Cush RheumNow ( View Tweet)